Intervention

Doravirine

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 15 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15

Recruiting3

Common conditions10

Lead sponsors shown9

Clinical trials

15 shown

Doravirine Dose Optimisation in PregnancyNCT05630638 · 2023-10-10

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy SwitchNCT04892654 · 2022-08-17

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)NCT04375800 · 2021-02-03

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"NCT05761509 · 2023-06-08

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant WomenNCT04900974 · 2022-06-09

HIV A6 Genome In ART Unsuccessful Patients On DORNCT05322083 · 2022-05-01

Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge).NCT05202613 · 2022-01-04

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)NCT04689737 · 2021-03-20

HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI ResistanceNCT04334551 · 2020-06-23

Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy VolunteersNCT03894124 · 2019-06-12

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)NCT03272347 · 2017-11-27

Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)NCT02715700 · 2015-09-28

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)NCT02275780 · 2014-12-01

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)NCT01632345 · 2012-10-12

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)NCT01466985 · 2011-10-21

Common conditions

HIV Infections4 HIV2 HIV-1 Infection2 Human Immunodeficiency Virus (HIV) Infection2 HIV-11 HIV-1-infection1 HIV-infected Participants With ESRD Undergoing Routine Hemodialysis1 Human Immunodeficiency Virus1 Pregnancy Related1 Virus-HIV1

Leading sponsors

Merck Sharp & Dohme LLC 6 Chelsea and Westminster NHS Foundation Trust 2 Clinique du Quartier Latin 1 Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia 1 Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 1 Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba 1 University of Liverpool 1 University of North Carolina, Chapel Hill 1 University of Roma La Sapienza 1

Trial status mix

COMPLETED9

RECRUITING3

UNKNOWN3

Phase mix

PHASE14

PHASE23

PHASE43

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.